Tango Therapeutics, Inc.(TNGX)

$31.63—

Chart

Tango Therapeutics, Inc.(TNGX)

NASDAQ

$31.63—

Chart Studio

TNGX(TNGX)

TNGX

Overview Notebook Intelligence Chart History Fundmntls TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q3 2026 EPS Estimate

$-0.31

Aug 4, 2026 · Reports before open

Revenue Estimate

$2M

FY2030E EPS$1.16

Analyst Sentiment

Wall St. Consensus

Buy

13 analysts·Moderate coverage

Score

12 Buy (92%)1 Hold (8%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

1292%

Hold

18%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$24.00

-23.8%

Consensus

$43.00

+36.5%

Bull

$69.00

+119.0%

12-Month Target Range13 analysts

$24.00$43.00$69.00

Current $31.50Consensus

Current Price

$31.50

Upside to Consensus

$11.50

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev-35.22%

EPS—

FY2028

Rev+1485.15%

EPS—

FY2029

Rev+331.79%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$6M	$4M	$62M	$269M	$741M
Low	$6M	$4M	$62M	$269M	$741M
High	$6M	$4M	$62M	$269M	$741M
EBITDA Avg	$-6M	$-4M	$-62M	$-269M	$-741M
Low	$-6M	$-4M	$-62M	$-269M	$-741M
High	$-6M	$-4M	$-62M	$-269M	$-741M
EBIT Avg	$-6M	$-4M	$-62M	$-269M	$-741M
Low	$-6M	$-4M	$-62M	$-269M	$-741M
High	$-6M	$-4M	$-62M	$-269M	$-741M
Net Income Avg	$-153M	$-173M	$-181M	$-115M	$135M
Low	$-170M	$-207M	$-229M	$-115M	$135M
High	$-136M	$-139M	$-132M	$-115M	$135M
EPS Avg	$-1.30	$-1.54	$-1.67	$-0.99	$1.16
Low	$-1.46	$-1.78	$-1.97	$-0.99	$1.16
High	$-1.17	$-1.20	$-1.14	$-0.99	$1.16
Analysts (Rev / EPS)	7 / 10	7 / 8	10 / 9	5 / 3	5 / 3

Quarterly

Metric	Q2 2026	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$2M	$3M	$636,727	$1M	$1M	$1M	$1M
Low	$2M	$3M	$636,727	$1M	$1M	$1M	$1M
High	$2M	$3M	$636,727	$1M	$1M	$1M	$1M
EBITDA Avg	$-2M	$-3M	$-636,727	$-1M	$-1M	$-1M	$-1M
Low	$-2M	$-3M	$-636,727	$-1M	$-1M	$-1M	$-1M
High	$-2M	$-3M	$-636,727	$-1M	$-1M	$-1M	$-1M
EBIT Avg	$-2M	$-3M	$-636,727	$-1M	$-1M	$-1M	$-1M
Low	$-2M	$-3M	$-636,727	$-1M	$-1M	$-1M	$-1M
High	$-2M	$-3M	$-636,727	$-1M	$-1M	$-1M	$-1M
Net Income Avg	$-46M	$-47M	$-49M	$-49M	$-53M	$-55M	$-56M
Low	$-52M	$-56M	$-49M	$-49M	$-53M	$-55M	$-56M
High	$-43M	$-39M	$-49M	$-49M	$-53M	$-55M	$-56M
EPS Avg	$-0.32	$-0.33	$-0.34	$-0.34	$-0.37	$-0.38	$-0.39
Low	$-0.36	$-0.39	$-0.34	$-0.34	$-0.37	$-0.38	$-0.39
High	$-0.30	$-0.27	$-0.34	$-0.34	$-0.37	$-0.38	$-0.39
Analysts (Rev / EPS)	11 / 8	8 / 8	5 / 6	5 / 3	6 / 5	9 / 3	5 / 6

Earnings Surprises

Recent Analyst Actions

Jun 29, 2026Canaccord Genuity

Tango Therapeutics price target raised to $46 from $42 at Canaccord

Target:$46.00

+46.2%from $31.47

Jun 25, 2026Jefferies

Tango Therapeutics upgraded to Buy from Hold at Jefferies

Target:$60.00

+99.1%from $30.14

Jun 9, 2026H.C. Wainwright

Tango Therapeutics price target raised to $66 from $27 at H.C. Wainwright

Target:$66.00

+113.0%from $30.98

Jun 9, 2026Canaccord Genuity

Tango Therapeutics price target raised to $42 from $30 at Canaccord

Target:$42.00

+35.8%from $30.93

Jun 8, 2026Leerink Partners

Tango Therapeutics price target raised to $69 from $55 at Leerink

Target:$69.00

+121.4%from $31.17

Jun 8, 2026Mizuho Securities

Tango Therapeutics price target raised to $36 from $30 at Mizuho

Target:$36.00

+15.8%from $31.08

Jun 8, 2026Wolfe Research

Tango Therapeutics upgraded to Outperform from Peer Perform at Wolfe Research

Target:$35.00

+18.3%from $29.59

May 15, 2026Mizuho Securities

Tango Therapeutics price target raised to $30 from $20 at Mizuho

Target:$30.00

+20.6%from $24.87

May 14, 2026Piper Sandler

Piper Sandler cuts Tango Therapeutics Neutral following Q1 report

Target:$24.00

-3.5%from $24.87

May 14, 2026UBS

Tango Therapeutics price target raised to $55 from $28 at Leerink

Target:$55.00

+121.1%from $24.87

May 14, 2026Wedbush

Tango Therapeutics price target raised to $33 from $19 at Wedbush

Target:$33.00

+37.6%from $23.98

May 14, 2026Jefferies

Tango Therapeutics downgraded to Hold from Buy at Jefferies

Target:$27.00

+5.8%from $25.51

Apr 27, 2026Stifel Nicolaus

Tango Therapeutics price target raised to $40 from $24 at Stifel

Target:$40.00

+55.3%from $25.75

Mar 9, 2026Stifel Nicolaus

Tango Therapeutics price target raised to $24 from $15 at Stifel

Target:$24.00

+45.9%from $16.45

Mar 5, 2026Jefferies

Tango Therapeutics Inc. (TNGX) PT Raised to $18 at Jefferies

Target:$18.00

+7.0%from $16.83

Feb 23, 2026Mizuho Securities

Tango Therapeutics initiated with an Outperform at Mizuho

Target:$19.00

+55.7%from $12.20

Jan 16, 2026Piper Sandler

Tango Therapeutics price target raised to $14 from $11 at Piper Sandler

Target:$14.00

+19.8%from $11.69

Dec 3, 2025Stifel Nicolaus

Tango Therapeutics initiated with a Buy at Stifel

Target:$15.00

+56.7%from $9.57

Oct 24, 2025Guggenheim

Tango Therapeutics price target raised to $12 from $10 at Guggenheim

Target:$12.00

+52.9%from $7.85

Sep 17, 2024Piper Sandler

Piper Sandler Reiterates Overweight Rating on Tango Therapeutics Inc. (TNGX)

Target:$18.00

+100.7%from $8.97

Aug 8, 2024Wedbush

Tango Therapeutics price target raised to $13 from $11 at Wedbush

Target:$13.00

+49.1%from $8.72

May 28, 2024H.C. Wainwright

Tango Therapeutics price target lowered to $13 from $16 at H.C. Wainwright

Target:$13.00

+88.1%from $6.91

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance